Gerresheimer AG : Not only 2024, but also 2025
>Cut to ambitious 2024 outlook…. - Gerresheimer announced the reduction of its 2024 guidance to 3-4% organic growth now (from 5% to 10% before) due to a significantly slower-than-expected market recovery. The guidance is also affected by the current flooding at the Morganton vial plant in the United States caused by Hurricane Helene, which will halt production for several weeks. We acknowledge that our Q3 organic growth forecast of 3.3% would have implied a strong acc...Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.